About this trial
The purpose of the study is to identify causes of chest pain in patients experiencing chest pain with no signs of narrowing of the coronary arteries of the heart, and to investigate whether physical exercise can improve coronary microvascular function.
Hypotheses:
The first hypothesis is that in INOCA, with reduced function of microvasculature of the heart, this reduced function also occurs in other organs of the body.
The second hypothesis is that regular physical activity (aerobic exercise training) can improve coronary microvascular function, reduce symptoms, and that there is a parallel improvement in vascular function in other organs of the body.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Coronary microvascular dysfunction, defined as myocardial bloodflow reserve (MBFR) < 2.5 or hyperemic myocar-dial blood flow (hMBF)<2.3 ml/g/min using [15O]H2O-PET
No obstructive coronary artery disease
Disqualifiers
Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile
Heart failure, defined as left ventricular ejection fraction of less than 40%
Uncontrolled hypertension defined as blood pressure above target 140/90 for all
Co-morbidity resulting in <1 year expected survival
Trial design
Parallel
Treatments tested in this trial
Exercise training
Other interventionThe training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised . Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels. Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment.
Treatment groups
Trial outcomes
Primary outcomes
Change in Myocardial Blood Flow Reserve (MBFR)
Change in MBFR assessed by \[15O\]H2O-PET-scan
Secondary outcomes
Change in symptom burden assessed by Seattle Angina Questionnaire
Seattle angina questionnaire/selfreported (scale range 0-100, 0=poor and 100=excellent health status)
Change in exercise capacity
Oxygen uptake during exhaustive exercise
Change in global rest perfusion in patients with angina symptoms and CMD
Change in Myocardial Blood Flow assessed by \[15O\]H2O-PET-scan
Change in global stress perfusion in patients with angina symptoms and CMD
Change in hyperemic Myocardial Blood Flow assessed by \[15O\]H2O-PET-scan
Other outcomes
Vascular Function Adaptations
Changes in Arterial compliance (C = ΔV/ ΔP) calculated from intraarterial pressure ΔP and arterial diameter (ΔD) measured by ultrasound Doppler
Changes in skin microvascular function
Hand microcirculatory blood flow assessed by Laser Speckle Contrast Imaging
Change in plasma levels of markers related to vascular function
Plasma levels of markers related to vascular function assessed by Mesoscale/ELISA
Changes in Arterial Blood Pressure
Assessed by automated blood pressure at rest
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Bispebjerg Hospital
Lead sponsor
University of Copenhagen
Collaborator